# A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD)

> **NCT02056808** · PHASE1 · COMPLETED · sponsor: **Summit Therapeutics** · enrollment: 12 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** SMT C1100

## Key facts

- **NCT ID:** NCT02056808
- **Lead sponsor:** Summit Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2014-05
- **Final completion:** 2014-07
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2014-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02056808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02056808, "A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02056808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*